Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases

Ana S.M. Afonso; Sven Schmiedl; Claudia Becker; Paola Primatesta; Estel Plana; Patrick C. Souverein; Joke C. Korevaar; Joerg Hasford; Robert Reynolds; Mark C.H. De Groot; Raymond G. Schlienger; Olaf H. Klungel; Marietta Rottenkolber

doi:10.1002/pds.3701

Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases

Ana S.M. Afonso, Sven Schmiedl, Claudia Becker, Paola Primatesta, Estel Plana, Patrick C. Souverein, Joke C. Korevaar, Joerg Hasford, Robert Reynolds, Mark C.H. De Groot, Raymond G. Schlienger, Olaf H. Klungel, Marietta Rottenkolber

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Meeting Abstract › Other research output

Abstract

Background: Results from multiple observational studies on inhaled long-acting beta-2-agonists (LABA) and the risk of acute myocardial infarction (AMI) are conflicting, due to variations in methodological, clinical and health care characteristics. To some extent, the discrepancies in the design might limit the comparability of the results encountered. Objectives: To determine the risk of AMI in inhaled LABA users in two European electronic primary care databases using a common study protocol. Methods: Patients from the Dutch Mondriaan (1.4 Million) and the UK CPRD (5 Million) databases were included if they had a diagnosis of asthma and/or COPD, and were prescribed at least one inhaled LABA, a short-acting beta-2-agonist (SABA), or a short- or long-acting muscarinic antagonist (SAMA, LAMA) during the study period (2002 to 2009). LABA episodes were divided into current, recent (

Original language	English
Article number	727
Pages (from-to)	390-391
Number of pages	2
Journal	Pharmacoepidemiology and Drug Safety
Volume	23
Issue number	S1
DOIs	https://doi.org/10.1002/pds.3701
Publication status	Published - 1 Oct 2014

Keywords

beta 2 adrenergic receptor stimulating agent
muscarinic receptor blocking agent
risk
infarction
data base
pharmacoepidemiology
risk management
human
patient
asthma
implantable cardioverter defibrillator
prescription
drug therapy
primary medical care
potential difference
health care
acute heart infarction
morbidity
model
proportional hazards model
diagnosis
United Kingdom
confidence interval
hazard ratio
observational study

Access to Document

10.1002/pds.3701

Embargoed Document

afonso_inhaled_2014
Final published version, 85 KB
Embargo ends: 1/01/50

Cite this

Afonso, A. S. M., Schmiedl, S., Becker, C., Primatesta, P., Plana, E., Souverein, P. C., Korevaar, J. C., Hasford, J., Reynolds, R., De Groot, M. C. H., Schlienger, R. G., Klungel, O. H., & Rottenkolber, M. (2014). Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases. Pharmacoepidemiology and Drug Safety, 23(S1), 390-391. Article 727. https://doi.org/10.1002/pds.3701

@article{467db9c47864421a91560cb6339ddad0,

title = "Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases",

abstract = "Background: Results from multiple observational studies on inhaled long-acting beta-2-agonists (LABA) and the risk of acute myocardial infarction (AMI) are conflicting, due to variations in methodological, clinical and health care characteristics. To some extent, the discrepancies in the design might limit the comparability of the results encountered. Objectives: To determine the risk of AMI in inhaled LABA users in two European electronic primary care databases using a common study protocol. Methods: Patients from the Dutch Mondriaan (1.4 Million) and the UK CPRD (5 Million) databases were included if they had a diagnosis of asthma and/or COPD, and were prescribed at least one inhaled LABA, a short-acting beta-2-agonist (SABA), or a short- or long-acting muscarinic antagonist (SAMA, LAMA) during the study period (2002 to 2009). LABA episodes were divided into current, recent (",

keywords = "beta 2 adrenergic receptor stimulating agent, muscarinic receptor blocking agent, risk, infarction, data base, pharmacoepidemiology, risk management, human, patient, asthma, implantable cardioverter defibrillator, prescription, drug therapy, primary medical care, potential difference, health care, acute heart infarction, morbidity, model, proportional hazards model, diagnosis, United Kingdom, confidence interval, hazard ratio, observational study",

author = "Afonso, {Ana S.M.} and Sven Schmiedl and Claudia Becker and Paola Primatesta and Estel Plana and Souverein, {Patrick C.} and Korevaar, {Joke C.} and Joerg Hasford and Robert Reynolds and {De Groot}, {Mark C.H.} and Schlienger, {Raymond G.} and Klungel, {Olaf H.} and Marietta Rottenkolber",

note = "Special Issue: Abstracts of the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, October 24–27, 2014, Taipei, Taiwan",

year = "2014",

month = oct,

day = "1",

doi = "10.1002/pds.3701",

language = "English",

volume = "23",

pages = "390--391",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "John Wiley and Sons Ltd",

number = "S1",

}

Afonso, ASM, Schmiedl, S, Becker, C, Primatesta, P, Plana, E, Souverein, PC, Korevaar, JC, Hasford, J, Reynolds, R, De Groot, MCH, Schlienger, RG, Klungel, OH & Rottenkolber, M 2014, 'Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases', Pharmacoepidemiology and Drug Safety, vol. 23, no. S1, 727, pp. 390-391. https://doi.org/10.1002/pds.3701

Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases. / Afonso, Ana S.M.; Schmiedl, Sven; Becker, Claudia et al.
In: Pharmacoepidemiology and Drug Safety, Vol. 23, No. S1, 727, 01.10.2014, p. 390-391.

Research output: Contribution to journal › Meeting Abstract › Other research output

TY - JOUR

T1 - Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases

AU - Afonso, Ana S.M.

AU - Schmiedl, Sven

AU - Becker, Claudia

AU - Primatesta, Paola

AU - Plana, Estel

AU - Souverein, Patrick C.

AU - Korevaar, Joke C.

AU - Hasford, Joerg

AU - Reynolds, Robert

AU - De Groot, Mark C.H.

AU - Schlienger, Raymond G.

AU - Klungel, Olaf H.

AU - Rottenkolber, Marietta

N1 - Special Issue: Abstracts of the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, October 24–27, 2014, Taipei, Taiwan

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: Results from multiple observational studies on inhaled long-acting beta-2-agonists (LABA) and the risk of acute myocardial infarction (AMI) are conflicting, due to variations in methodological, clinical and health care characteristics. To some extent, the discrepancies in the design might limit the comparability of the results encountered. Objectives: To determine the risk of AMI in inhaled LABA users in two European electronic primary care databases using a common study protocol. Methods: Patients from the Dutch Mondriaan (1.4 Million) and the UK CPRD (5 Million) databases were included if they had a diagnosis of asthma and/or COPD, and were prescribed at least one inhaled LABA, a short-acting beta-2-agonist (SABA), or a short- or long-acting muscarinic antagonist (SAMA, LAMA) during the study period (2002 to 2009). LABA episodes were divided into current, recent (

AB - Background: Results from multiple observational studies on inhaled long-acting beta-2-agonists (LABA) and the risk of acute myocardial infarction (AMI) are conflicting, due to variations in methodological, clinical and health care characteristics. To some extent, the discrepancies in the design might limit the comparability of the results encountered. Objectives: To determine the risk of AMI in inhaled LABA users in two European electronic primary care databases using a common study protocol. Methods: Patients from the Dutch Mondriaan (1.4 Million) and the UK CPRD (5 Million) databases were included if they had a diagnosis of asthma and/or COPD, and were prescribed at least one inhaled LABA, a short-acting beta-2-agonist (SABA), or a short- or long-acting muscarinic antagonist (SAMA, LAMA) during the study period (2002 to 2009). LABA episodes were divided into current, recent (

KW - beta 2 adrenergic receptor stimulating agent

KW - muscarinic receptor blocking agent

KW - risk

KW - infarction

KW - data base

KW - pharmacoepidemiology

KW - risk management

KW - human

KW - patient

KW - asthma

KW - implantable cardioverter defibrillator

KW - prescription

KW - drug therapy

KW - primary medical care

KW - potential difference

KW - health care

KW - acute heart infarction

KW - morbidity

KW - model

KW - proportional hazards model

KW - diagnosis

KW - United Kingdom

KW - confidence interval

KW - hazard ratio

KW - observational study

U2 - 10.1002/pds.3701

DO - 10.1002/pds.3701

M3 - Meeting Abstract

SN - 1053-8569

VL - 23

SP - 390

EP - 391

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

IS - S1

M1 - 727

ER -

Association between inhaled long-acting beta-2-agonists and the risk of acutemyocardial infarction: A methodological comparison of two databases

Abstract

Keywords

Access to Document

Embargoed Document

Fingerprint

Cite this